The trademark application YMBEOS was filed by Eli Lilly and Company, a U.S. corporation (the "Applicant"). The application was published for oppositions on December 9, 2020, and it was registered by office on March 18, 2021 without any oppositions.
The application was filed in English (Italian was selected as the second language).
Appointment and Replacement of representative of the trademark registration was recorded on November 23, 2020.
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations namely, pharmaceutical preparations for the prevention, diagnosis and/or treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, and cluster headaches
Pharmaceutical preparations for the prevention, diagnosis and/or treatment of Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, pharmaceutical preparations for the prevention, diagnosis and/or treatment of gastrointestinal diseases and disorders, headaches, heart failure, and hypoglycaemia
Pharmaceutical preparations for the prevention, diagnosis and/or treatment of inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders
Pharmaceutical preparations for the prevention, diagnosis and/or treatment of neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, and ulcerative colitis
Diagnostic agents and substances for medical purposes
Radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases and of oncology and of pain